Radiopharm Theranostics Limited RADX

Annual Quarterly

FY2025 · ended Jun 30, 2025 · Revenue $3.63M · Filed Sep 18, 2025

Radiopharm Theranostics Limited (RADX) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Jun 30, 2025, it reported revenue of $3.6 million and a net loss of $38.3 million.

Revenue
$3.63M
Net income
$-38.34M
Operating cash flow
$-36.65M
Free cash flow
—
EPS
$-1.76
Dividend per share
None
Shares outstanding
3.54B
+49.9% vs prior year
Net cash
—
Operating margin
-1050.6%
FY 2025

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
RADX (Nasdaq), RDPTF (OTC)
Fiscal year ends
June 30
Incorporated in
Australia
Headquarters
Carlton Vic
SEC filer status
Non-accelerated filer, Emerging growth company
SEC CIK
1949257

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Key figures

Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.

FY 2025
Jun 30, 2025
Revenue
$3.6M
Operating income
-$38.2M
Net income
-$38.3M
Diluted EPS
-$1.76
Operating cash flow
-$36.6M
Total assets
$86.5M
Total liabilities
$43.6M
Stockholders' equity
$42.9M
Cash and investments
$29.1M

Recent SEC filings

Form Description Filed Period
6-K Current report (foreign issuer) Nov 4, 2026 Nov 4, 2026
6-K Current report (foreign issuer) Oct 30, 2026 Oct 30, 2026
6-K Current report (foreign issuer) Oct 27, 2026 Oct 27, 2026
6-K Current report (foreign issuer) Oct 26, 2026 Oct 26, 2026
6-K Current report (foreign issuer) Oct 20, 2026 Oct 20, 2026
6-K Current report (foreign issuer) Oct 5, 2026 Oct 5, 2026

All 163 Radiopharm Theranostics Limited SEC filings

Source: SEC EDGAR filings. This is company-reported data, not investment advice.